ITMCTR2100005029尚未招募1 期
Zhitan anshen granules for convalescent cerebral infarction: a randomized controlled, double-blind trial
Xinhua Hospital Affiliated to Hubei University of Traditional Chinese Medicine/Hubei Provincial Hospital of Integrated Chinese and Western Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 40 至 75（—）
- 性别
- All
入选标准
- •1. Meet the diagnostic criteria of ''cerebral infarction'' and be confirmed by head CT or MRI examination;
- •2. Meet the standard of traditional Chinese medicine for stroke-qi deficiency and blood stasis syndrome;
- •3. In the recovery period (the course of the disease is 2 weeks to 6 months);
- •4. Aged 40 to 75 years;
- •5. For the first time, the vital signs are stable, the consciousness is clear, and the patient can cooperate with the examination and treatment;
- •6. Voluntarily participate in this study and sign the informed consent.
排除标准
- •1. Patients with severe cardiovascular and cerebrovascular, liver, kidney, malignant tumors, blood system diseases, and mental diseases;
- •2. Severe disturbance of consciousness, dementia or certain diseases that affect the evaluation of curative effect, such as aphasia, audio-visual impairment;
- •3. Transient organic psychosis and other psychotic disorders (such as depression, schizophrenia), or other mental disorders that meet the DSM-IV-R criteria;
- •4. Patients with other diseases that affect the function of limb movement, and those with limb movement dysfunction caused by claudication, osteoarthritis, rheumatoid arthritis, gouty arthritis, etc., which may affect the nerve or functional examination before treatment;
- •5. Those who are allergic to the components of the test drug, or have a history of alcohol or drug abuse;
- •6. Patients who are pregnant or breastfeeding, or who plan to become pregnant within the past 6 months, or who cannot use effective contraceptive measures (sterilization, long-term use of contraceptives/dose, condoms, or partner removal of the vas deferens, etc.);
- •7. Those who are participating in other clinical trials or have participated in other drug clinical trials within 3 months;
- •8. Patients who are judged by the investigator to be unsuitable to participate in this trial.
研究者
相似试验
尚未招募
1 期
Jiannao tongluo granules for convalescent cerebral infarction: a randomized controlled, double-blind trialcerebral InfarctionITMCTR2100005030Xinhua Hospital Affiliated to Hubei University of Traditional Chinese Medicine/Hubei Provincial Hospital of Integrated Chinese and Western Medicine
尚未招募
1 期
Qingkepingchuan granules for acute exacerbation of COPD patients with syndrome of phlegm heat obstructing lung: a randomized, double-blind, placebo-controlled trialChronic obstructive pulmonary diseaseITMCTR2100004373Guangdong Provincial Hospital of Chinese Medicine
招募中
不适用
Clinical trial of Xuhanting granule in the treatment of children's recurrent respiratory tract infectionsITMCTR2100004538Guangdong Women and Children Hospital
已完成
2 期
Clinical study to assess treatment effects of Cerebrolysin in amyotrophic lateral sclerosisMotor neuron diseaseISRCTN38393880Instituto Cardiológico Banfield20
进行中（未招募）
不适用
CHANT (Cerebral Hemorrhage And NXY Treatment)A double-blind, randomized, placebo-controlled, parallel-group, multicenter, phase IIb study to assess the safety and tolerability of 72 hours intravenous infusion of NXY 059 in adult patients with acute intracerebral hemorrhage (ICH) - CHANTEUCTR2004-000566-12-SEAstraZeneca AB600